Proactive Investors - Run By Investors For Investors

Futura Medical on the rise as Liberum says newspaper article could spark interest in group’s main ED product

Over the weekend The Guardian published an in-depth piece on the emerging treatments for erectile dysfunction (ED) with a significant focus on Futura's MED2005 product
Couple in bed
“This will help to drive interest in what appears to be a very over-looked product in terms of its potential to address a very large market," Liberum's analysts said

Futura Medical PLC (LON:FUM) saw its shares shoot higher on Monday after ‘house’ broker Liberum Capital highlighted an article published in ‘The Guardian’ newspaper which could spark interest in the group’s main product.

In a note to clients, the City broker’s analysts pointed out that over the weekend the newspaper published an in-depth piece on the emerging treatments for erectile dysfunction (ED) with a significant focus on the AIM-listed firm’s MED2005 which is in a P3 study due to read-out by the end of the year.

READ: Futura Medical trial on track to deliver “major value inflection point”

They said: “The article highlights the lack of clinical advances in ED over the past 20 years and the emerging opportunity for products that can address the shortcomings of the PDe-5 inhibitor class (Viagra) with MED2005 appearing to offer convenience and side-effect profile benefits.”

The analysts concluded: “This will help to drive interest in what appears to be a very over-looked product in terms of its potential to address a very large market.”

In afternoon trading, shares in Futura Medical were up 11.6% at 23.15p.

View full FUM profile View Profile

Futura Medical PLC Timeline

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use